Abstract
Purpose :
Recently, minimally invasive glaucoma surgery (MIGS) techniques have been developed to reduce the complications of conventional filtering surgeries that can affect the functional prognosis of our patients. The purpose of our study is to present the results at 1 year in patients who had surgery with XEN® Implant (Allergan Inc., Irvine, CA, USA) in combination with 5-Fluorouracil.
Methods :
We included, retrospectively, all patients who had XEN surgery (standalone or combined with cataract surgery) in our department. Patients underwent a subconjunctival injection of 0.01mL of 5-Fluorouracil at the site of XEN implantation at the beginning of the procedure. We collected retrospectively: intra-ocular pression (IOP), number IOP lowering treatment, per and postoperative complications and needling procedure during postoperative follow-up. Data were collected before, Day 1, Month 1, 6, 9 and 12 after the procedure.
Results :
We included 24 eyes of 23 patients. The mean age is 76.6 +/- 8.3years. The mean MD is -10.5dB +/- 7. The IOP before procedure is 19.3mmHg +/- 4.9. At 12 months after the procedure, IOP is 13.8mmHg +/- 6.1 (-28.3% compared to initial IOP). The needling rate is 54.4%. It is realized 2.3 +/- 1.8months after the procedure. Visual acuity remained stable during follow-up. The number of IOP lowering treatments decreases from 3.3 +/- 0.8 treatments before the procedure to 1 +/- 1.4 treatments at 12 months after the procedure. The complications encountered are related to postoperative hypotonia and are transient. Two patients require a surgical management, the first patient in the fith post-operative days for a persistent athalamia and the second patient later (5 months post-op) for a partial migration of the implant into the anterior chamber.
Conclusions :
This study reports the efficacy of the XEN® implant (Allergan Inc., Irvine, CA, USA) with 5-Fluorouracil in the surgical management of glaucoma. The needling rate seems to be higher than other studies of the literature. These results must be confirmed by a series with more patients and a larger sample.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.